Zirconia Nanocomposite for Cancer Cell Studies
Official patent title
Method of treating cancer using a ZrO2@CaSiO3@g-C3N4 nanocomposite material
Arabic title: طريقة لعلاج السرطان باستخدام مادة مركبة نانوية من ZrO2@CaSiO3@g-C3N4
Invention
Invention
Problem
Cancer therapies can be limited by non-specific toxicity, low bioavailability, resistance, dose requirements, and delivery challenges, while biomedical nanomaterials introduce additional safety, clearance, and manufacturing concerns.
Why it matters
A nanocomposite that inhibits cultured cancer cells could be an early research lead, but in-vitro viability results do not establish tumor selectivity, animal efficacy, human safety, dosing, or clinical treatment benefit.
Approach
The method exposes MCF-7 or HepG-2 cancer-cell models to a ZrO2/CaSiO3/g-C3N4 material containing spherical oxide nanoparticles dispersed on carbon-nitride nanosheets.
Who may benefit
Potential beneficiaries include cancer nanomedicine researchers, cell-biology laboratories, materials-toxicology groups, oncology drug-discovery teams, and translational centers evaluating early-stage inorganic nanomaterials.
Potential value
The disclosure connects a structurally characterized three-component nanocomposite with reported MCF-7 and HepG-2 in-vitro viability endpoints and particle, surface-area, and pore properties.
Background
Background
Conventional chemotherapy can be constrained by systemic toxicity, resistance, solubility, bioavailability, dose, and targeting. Nanomaterials are investigated as active agents or delivery platforms because their size, shape, and surface can be modified, but biomedical use raises concerns about long-term toxicity, clearance, accumulation, reproducible manufacture, and clinical translation. The patent evaluates a zirconia/calcium-silicate/carbon-nitride composite against two cultured cancer-cell models. This evidence is limited to in-vitro viability and cannot support a conclusion about treatment in animals or patients.
Technology overview
Technology overview
The material has spherical ZrO2- and CaSiO3-phase nanoparticles dispersed on g-C3N4 nanosheets, with a claimed average particle diameter of 3–18 nm. The method exposes cancer cells to the composite. Claims report at least 80% inhibition for MCF-7 cells in an in-vitro viability assay and provide additional MCF-7 and HepG-2 inhibition and IC50 thresholds. They also specify BET surface-area thresholds, pore volume, and a trimodal pore-size distribution. No animal or clinical treatment evidence is established in the cited record.
Potential applications
Potential applications
- Potential in-vitro research with MCF-7 breast-cancer cells.
- Potential in-vitro research with HepG-2 liver-cancer cells.
- Potential nanomaterial cytotoxicity and mechanism studies.
- Potential preclinical lead evaluation after normal-cell selectivity testing.
Evidence-supported advantages
Evidence-supported advantages
- Defines ZrO2 and CaSiO3 nanoparticles on g-C3N4 nanosheets.
- Specifies a 3–18 nm average particle-diameter range.
- Reports viability-assay endpoints for two named cell models.
- Defines BET, pore-volume, and pore-size characteristics.
Development stage
Development stage
Patent publication describing material characterization and in-vitro cancer-cell viability assays; independent validation, animal or clinical efficacy, safety, and commercialization were not established.
Commercial opportunity
Commercial opportunity
The material may support early-stage cancer-nanomedicine research licensing. Translation requires independent replication, normal-cell selectivity, mechanism and uptake studies, biodistribution, clearance and accumulation, dose and route definition, formulation, sterility, immunotoxicity and genotoxicity, animal efficacy, comprehensive toxicology, reproducible medical-grade manufacture, and regulated clinical trials before any therapeutic use.
Patent classifications
Patent classifications
WIPO IPC
- A61K33/24Preparations for medical, dental or toiletry purposes
- A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
CPC
- A61K33/24Preparations for medical, dental or toiletry purposes
- A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
Inventors
Inventors
- First inventorMohamed Khairy Abdel Fattah Omran
- InventorBabiker Yagoub Elhadi Abdulkhair
Keywords
Keywords
- ZrO2
- CaSiO3
- g-C3N4
- nanocomposite
- MCF-7
- HepG-2
- in-vitro viability
- cancer research
Patent document and drawings
Patent document and drawings
The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.